Helen Y Chu1, Mark C Steinhoff2, Amalia Magaret3, Khalequ Zaman4, Eliza Roy4, Gretchen Langdon2, Mary Anne Formica5, Edward E Walsh5, Janet A Englund6. 1. Department of Medicine. 2. Department of Global Health, Cincinnati Children's Hospital, Ohio. 3. Department of Laboratory Medicine, University of Washington. 4. International Center for Diarrheal Disease Research, Dhaka, Bangladesh. 5. Department of Medicine, University of Rochester-Rochester General Hospital, New York. 6. Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington.
Abstract
BACKGROUND: Pneumonia is the leading cause of childhood mortality globally. Respiratory syncytial virus (RSV) is the most important viral cause of pneumonia. Maternal serum antibody protects infants from RSV disease. The objective of our study was to characterize RSV antibody levels in mother-infant pairs. METHODS: Serial serum samples were collected from mother-infant pairs in Bangladesh from the third trimester of pregnancy to 72 weeks postpartum and tested using an RSV antibody microneutralization assay. Serologic infection was defined as a 4-fold increase in antibody titer. Maternal antibody half-life was calculated using infant antibody titers from birth to 20 weeks. RESULTS: The ratio of infant cord blood to maternal serum RSV antibody titers in 149 mother-infant pairs was 1.01 (95% confidence interval [CI], .99-1.03). Maternal RSV antibody titers in the third trimester and at birth were strongly correlated (R = 0.68). Antibody half-life was 38 days (95% CI, 36-42 days). Higher cord blood RSV antibody titers were associated with a lower risk of serologic infection (P = .01) and maintenance of antibody titer above a potentially protective threshold (P < .001). CONCLUSIONS: Efficient transplacental transfer of RSV-specific antibody from mother to the fetus was documented in mother-infant pairs in Asia. Higher cord blood antibody titers were associated with protection from serologic infection.
RCT Entities:
BACKGROUND:Pneumonia is the leading cause of childhood mortality globally. Respiratory syncytial virus (RSV) is the most important viral cause of pneumonia. Maternal serum antibody protects infants from RSV disease. The objective of our study was to characterize RSV antibody levels in mother-infant pairs. METHODS: Serial serum samples were collected from mother-infant pairs in Bangladesh from the third trimester of pregnancy to 72 weeks postpartum and tested using an RSV antibody microneutralization assay. Serologic infection was defined as a 4-fold increase in antibody titer. Maternal antibody half-life was calculated using infant antibody titers from birth to 20 weeks. RESULTS: The ratio of infant cord blood to maternal serum RSV antibody titers in 149 mother-infant pairs was 1.01 (95% confidence interval [CI], .99-1.03). Maternal RSV antibody titers in the third trimester and at birth were strongly correlated (R = 0.68). Antibody half-life was 38 days (95% CI, 36-42 days). Higher cord blood RSV antibody titers were associated with a lower risk of serologic infection (P = .01) and maintenance of antibody titer above a potentially protective threshold (P < .001). CONCLUSIONS: Efficient transplacental transfer of RSV-specific antibody from mother to the fetus was documented in mother-infant pairs in Asia. Higher cord blood antibody titers were associated with protection from serologic infection.
Authors: Harish Nair; W Abdullah Brooks; Mark Katz; Anna Roca; James A Berkley; Shabir A Madhi; James Mark Simmerman; Aubree Gordon; Masatoki Sato; Stephen Howie; Anand Krishnan; Maurice Ope; Kim A Lindblade; Phyllis Carosone-Link; Marilla Lucero; Walter Ochieng; Laurie Kamimoto; Erica Dueger; Niranjan Bhat; Sirenda Vong; Evropi Theodoratou; Malinee Chittaganpitch; Osaretin Chimah; Angel Balmaseda; Philippe Buchy; Eva Harris; Valerie Evans; Masahiko Katayose; Bharti Gaur; Cristina O'Callaghan-Gordo; Doli Goswami; Wences Arvelo; Marietjie Venter; Thomas Briese; Rafal Tokarz; Marc-Alain Widdowson; Anthony W Mounts; Robert F Breiman; Daniel R Feikin; Keith P Klugman; Sonja J Olsen; Bradford D Gessner; Peter F Wright; Igor Rudan; Shobha Broor; Eric A F Simões; Harry Campbell Journal: Lancet Date: 2011-11-10 Impact factor: 79.321
Authors: Demilade A Adedinsewo; Laila Noory; Robert A Bednarczyk; Mark C Steinhoff; Robert Davis; Chinelo Ogbuanu; Saad B Omer Journal: Vaccine Date: 2013-10-10 Impact factor: 3.641
Authors: Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes Journal: PLoS One Date: 2009-12-02 Impact factor: 3.240
Authors: Jorge C G Blanco; Lurds R Fernando; Wei Zhang; Arash Kamali; Marina S Boukhvalova; Lori McGinnes-Cullen; Trudy G Morrison Journal: J Virol Date: 2019-11-13 Impact factor: 5.103
Authors: Jorge C G Blanco; Lioubov M Pletneva; Raymonde O Oue; Mira C Patel; Marina S Boukhvalova Journal: Vaccine Date: 2015-08-31 Impact factor: 3.641
Authors: Jessica E Atwell; Bhagvanji Thumar; Leanne J Robinson; Roselyn Tobby; Phantica Yambo; Maria Ome-Kaius; Peter M Siba; Holger W Unger; Stephen J Rogerson; Christopher L King; Ruth A Karron Journal: J Infect Dis Date: 2015-08-03 Impact factor: 5.226